M&T Bank Corp Buys Shares of 23,774 Artivion, Inc. (NYSE:AORT)

M&T Bank Corp bought a new stake in Artivion, Inc. (NYSE:AORTGet Rating) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 23,774 shares of the company’s stock, valued at approximately $435,000. M&T Bank Corp owned about 0.06% of Artivion as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Royce & Associates LP acquired a new stake in Artivion in the second quarter valued at approximately $16,219,000. Janney Montgomery Scott LLC bought a new position in shares of Artivion in the second quarter valued at approximately $727,000. Comerica Bank bought a new position in shares of Artivion in the second quarter valued at approximately $647,000. Los Angeles Capital Management LLC bought a new position in shares of Artivion in the second quarter valued at approximately $214,000. Finally, Nisa Investment Advisors LLC bought a new position in shares of Artivion in the second quarter valued at approximately $65,000. 85.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Artivion news, VP Rochelle L. Maney sold 7,161 shares of Artivion stock in a transaction on Tuesday, August 16th. The shares were sold at an average price of $22.96, for a total transaction of $164,416.56. Following the sale, the vice president now owns 12,325 shares in the company, valued at $282,982. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 5.60% of the stock is currently owned by insiders.

Artivion Trading Up 0.7 %

Shares of AORT stock opened at $12.19 on Monday. Artivion, Inc. has a 1 year low of $9.64 and a 1 year high of $23.43. The firm’s fifty day simple moving average is $14.32 and its 200 day simple moving average is $17.64. The firm has a market capitalization of $491.61 million, a P/E ratio of -11.72 and a beta of 1.36. The company has a current ratio of 5.17, a quick ratio of 3.59 and a debt-to-equity ratio of 1.22.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on AORT shares. Needham & Company LLC dropped their price target on shares of Artivion from $28.00 to $23.00 and set a “buy” rating on the stock in a research report on Friday, November 4th. Oppenheimer dropped their price target on shares of Artivion from $35.00 to $25.00 and set an “outperform” rating on the stock in a research report on Monday, September 26th. Morgan Stanley dropped their target price on shares of Artivion from $16.00 to $14.00 and set an “equal weight” rating on the stock in a research report on Tuesday, October 11th. Finally, Lake Street Capital dropped their target price on shares of Artivion from $32.00 to $28.00 and set a “buy” rating on the stock in a research report on Tuesday, September 27th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Artivion presently has an average rating of “Moderate Buy” and a consensus price target of $24.00.

About Artivion

(Get Rating)

Artivion Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo.

Read More

Institutional Ownership by Quarter for Artivion (NYSE:AORT)

Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.